DNA – BA-Merrill Lynch rates the stock as Buy

DNA – BA-Merrill Lynch rates the stock as Buy, High Risk

Donaco has slipped, affected by tensions between China and Vietnam. As long as this hangs over the stock the broker expects it to exhibit volatility. The broker believes there is scope for significant medium-term upgrades.

Valuation is undemanding so Merrills reiterates a Buy rating and $1.60 target.

Sector: Consumer Services.

Target price is $1.60.Current Price is $1.04. Difference: $0.56 – (brackets indicate current price is over target). If DNA meets the BA-Merrill Lynch target it will return approximately 35% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →